Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 12-Month Low at $111.11

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s share price reached a new 52-week low on Friday . The stock traded as low as $111.11 and last traded at $111.26, with a volume of 245497 shares. The stock had previously closed at $113.49.

Analyst Ratings Changes

JAZZ has been the subject of several recent research reports. Stifel Nicolaus raised their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, March 22nd. HC Wainwright lowered their price objective on Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research report on Thursday, March 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.08.

Jazz Pharmaceuticals Stock Performance

The stock has a 50 day simple moving average of $121.21 and a 200 day simple moving average of $123.15. The company has a market cap of $6.97 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 1.57 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, analysts predict that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Jazz Pharmaceuticals by 0.5% in the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after buying an additional 29,960 shares during the last quarter. Wellington Management Group LLP increased its holdings in Jazz Pharmaceuticals by 7.5% in the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after buying an additional 184,124 shares during the last quarter. State Street Corp increased its holdings in Jazz Pharmaceuticals by 1.8% in the second quarter. State Street Corp now owns 2,372,395 shares of the specialty pharmaceutical company’s stock valued at $294,106,000 after buying an additional 42,703 shares during the last quarter. LSV Asset Management increased its holdings in Jazz Pharmaceuticals by 2.4% in the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after buying an additional 55,630 shares during the last quarter. Finally, FMR LLC increased its holdings in Jazz Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after buying an additional 100,349 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.